

# EXHIBIT A



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/606,471	06/25/2003	Abram Katz	13425-115001 / BV-1025 US	3516
26161 7590 03/19/2008 FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER WOOD, AMANDA P	
			ART UNIT 1657	PAPER NUMBER
			MAIL DATE 03/19/2008	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/606,471	Applicant(s) KATZ ET AL.	
	Examiner AMANDA P. WOOD	Art Unit 1657	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 29 November 2007.
- 2a) ☒ This action is FINAL.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1,4,7 and 18-26 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,4,7 and 18-26 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)          | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

Applicant's response filed 29 November 2007 has been received and entered.

Claims 1, 4, 7, and 18-26 have been considered on the merits.

### ***Response to Arguments***

Based upon Applicant's arguments and further review of the instant application, the rejections dated 29 August 2007 for claims 1, 4, 7, and 18-26 under 35 U.S.C. 102 and 103 have been withdrawn. Applicant's arguments with respect to these claims and rejections have been considered but are moot in view of the new ground(s) of rejection.

### ***Maintained Rejections***

#### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4, 19, 22, and 25 stand rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. In particular, Applicant recites the phrase "contacting a candidate agent with a SMCE-regulating factor" in line 3 of claim 4 and the phrase "determining whether the candidate agent increases glucose uptake in a mammalian cell" in lines 6-7. The limitation of "determining whether the candidate agent increases glucose uptake in a mammalian cell" lacks antecedent basis with respect to the rest of claim 4, because the candidate agent is contacted with a SMCE-

regulating factor, not with the mammalian cell. It is unclear from the current phrasing of the claim how the increase in glucose uptake in a mammalian cell is linked with contacting a candidate agent with a SMCE-regulating factor (i.e., does the mammalian cell comprise a SMCE-regulating factor or something else?).

Furthermore, it is unclear what Applicant intends to encompass by "SMCE-regulating factor" in claim 4 (is this factor a cell, a protein, a peptide fragment, etc.?).

Claims 19, 22, and 25 depend directly or indirectly from rejected claims and are, therefore, also rejected under USC 112, second paragraph for the reasons set forth above.

### ***Response to Arguments***

Applicant's arguments filed 29 November 2007 have been fully considered but they are not persuasive. In particular, Applicant argues that the person of ordinary skill in the art would understand that the two determining steps are connected. However, it remains unclear how the steps of contacting a candidate agent with an SMCE-regulating factor and determining whether the agent stimulates a function of the SMCE-regulating factor relate to the last step of determining whether the candidate agent stimulates glucose uptake in a mammalian cell. There appears to be a gap between the steps in the claims, as drafted, since Applicant has not established the link between the "function of the SMCE-regulating factor" and the stimulation of glucose uptake in a mammalian cell in the claims. In addition, Applicant has not provided any specific

definition for "SMCE-regulating factor" in the instant specification. Applicant merely provides examples of what such a factor "could be."

***New Objections to the Claims***

***Claim Objection(s)***

Claims 4 and 7 are objected to because of the following informalities: The abbreviation SMCE should be spelled out at the first instance in each independent claim. Appropriate correction is required.

***New Rejection(s)***

***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 4, 7, and 18-26 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. In particular, Applicant recites the term "agent" and "candidate agent" in claims 1, 4, and 7. Applicant has not provided a clear definition in the instant specification which describes what is meant by "agent" or "candidate agent." Applicant states in the instant specification that candidate agents "encompass numerous chemical classes" but are "typically organic compounds" and can be "obtained from a wide variety of sources including libraries of synthetic or natural

compounds." Applicant further states that a candidate agent can contain, "for example, a peptide, peptidomimetic, amino acid analog, polynucleotide, nucleotide, nucleotide analog, or other small molecule" on page 5 of the instant specification. Applicant has not provided any particular species or compound which has been used in an experiment or assay for the claims as drafted (i.e., assays for identifying an agent that increases glucose uptake in a mammalian cell).

All other claims depend directly or indirectly from rejected claims and are, therefore, also rejected under USC 112, first paragraph for the reasons set forth above.

Claims 1, 4, 7, and 18-20 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for mammalian skeletal muscle cells, does not reasonably provide enablement for any and all mammalian cells. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether undue experimentation is required are summarized in *re Wands* 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir.1988). The court in *Wands* states: "Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to

make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations." (Wands, 8 USPQ2d 1404). The factors to be considered in determining whether undue experimentation is required include: (1) the breadth of the claims, (2) the nature of the invention, (3) the state of the prior art, (4) the predictability or unpredictability of the art, (5) the relative skill of those in the art, (6) the amount or direction or guidance presented, (7) the presence or absence of working examples, and (8) the quantity of experimentation necessary.

N.B. MPEP 2164.04 states, "[w]hile the analysis and conclusion of a lack of enablement are based on the factors discussed in MPEP § 2164.01(a) and the evidence as a whole, it is not necessary to discuss each factor in the written enablement rejection" and that "[t]he language should focus on those factors, reasons, and evidence that lead the examiner to conclude that the specification fails to teach how to make and use the claimed invention without undue experimentation, or that the scope of any enablement provided to one skilled in the art is not commensurate with the scope of protection sought by the claims." Accordingly, the Factors most relevant to the instant rejection are addressed in detail below.

1-2 .Breadth of the claims and the nature of the invention..

In regards to the method of the invention and the breadth of the claims the broadest interpretation that applies is a method for identifying agents which increase store-mediated calcium entry into mammalian cells and which also increase glucose uptake in mammalian cells.



5. The relative skill in the art.

The relative skill in the art as it relates to the method of the invention is characterized by that of a M.D. or Ph. D. level individual.

6-7. The amount of guidance present and the existence of working examples.

The working examples in the instant specification do not provide any guidance beyond using skeletal muscle cells in experiments for determining 2-deoxyglucose uptake in the presence and absence of a known antagonist of store-mediated calcium entry both with and without insulin. Applicant does not provide any guidance for identifying agents which increase glucose uptake in any mammalian cells other than skeletal muscle cells, nor does Applicant provide any particular guidance or examples of any specific agents which increase glucose uptake in either mammalian cells or in skeletal muscle cells specifically.

8. The quantity of experimentation necessary.

The amount of experimentation that is required is undue: while the assay method is routine, a method of identifying agents which increase glucose uptake in any and all mammalian cells is not routine and requires more experimentation. Therefore, in view of the overly broad scope of the claims, and the lack of guidance and working examples provided in the specification, undue experimentation would be necessary for a skilled artisan to make and use the entire scope of the claimed invention.

It must be noted that the issue in this case is the breadth of the claims in light of the predictability of the art as determined by the number of working examples, the skill level of the artisan and the guidance presented in the instant specification and the prior

Art Unit: 1652

art of record. The Applicants make and test position is inconsistent with the decisions of *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) where it is stated that "... scope of claims must bear a reasonable correlation to scope of enablement provided by the specification to persons of ordinary skill in the art...". Without sufficient guidance, determination of having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily and improperly extensive and undue. See *In re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

Therefore, for the instant specification to be enabling, it needs to provide

direction/guidance regarding an acceptable number of different mammalian cells.

Absent sufficient guidance/direction one of skill in the art would not be able to practice the claimed invention commensurate in scope with the claims. Thus, for all these reasons, the specification is not considered to be enabling for one skilled in the art to make and use the claimed invention as the amount of experimentation required is undue, due to the broad scope of the claims and the lack of guidance and insufficient working examples provided in the specification, attempting to test all the different types of cells encompassed by the claimed invention would constitute undue experimentation. Therefore, applicants have not provided sufficient guidance to enable one of skill in the art to make and use the claimed invention in a manner that reasonably correlates with the scope of the claims, to be considered enabling.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Art Unit: 1652

Claims 1, 4, 7, and 18-26 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1 recites the limitation "determining whether the candidate agent increases store-mediated  $\text{Ca}^{2+}$  entry (SMCE) into the cell" in lines 4-5. There is insufficient antecedent basis for this limitation in the claim. In particular, it is unclear from the preamble of claim 1 how the step of lines 4-5 relates to a method of identifying an agent that increases glucose uptake in a mammalian cell, since Applicant has not related an increase in store-mediated  $\text{Ca}^{2+}$  entry with an increase in glucose uptake in the instant claim.

Claim 4 recites the limitation "determining whether the candidate agent stimulates a function of the SMCE-regulating factor into the cell" in lines 4-5. There is insufficient antecedent basis for this limitation in the claim. In particular, it is unclear from the preamble of claim 1 how the step of lines 4-5 relates to a method of identifying an agent that increases glucose uptake in a mammalian cell, since Applicant has not related a stimulation of a function of a SMCE-regulating factor with an increase in glucose uptake in the instant claim.

Claim 7 recites the limitation "wherein the candidate agent increases SMCE into the cell" in lines 3-4. There is insufficient antecedent basis for this limitation in the claim. In particular, it is unclear from the preamble of claim 1 how the phrase of lines 3-4 relates to a method of identifying an agent that increases glucose uptake in a

mammalian cell, since Applicant has not related an increase in SMCE with an increase in glucose uptake in the instant claim.

All other claims depend directly or indirectly from rejected claims and are, therefore, also rejected under USC 112, second paragraph for the reasons set forth above.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 4, 7, and 18-26 are rejected under 35 U.S.C. 102(b) as being anticipated by You et al (Amer. J. Physiol. 1991).

A method is claimed for identifying an agent that increases glucose uptake in a mammalian cell comprising contacting a mammalian cell with a candidate agent, determining whether the candidate agent increases store-mediated  $\text{Ca}^{2+}$  entry into the cell, and determining whether the candidate agent increases glucose uptake in the cell.

Youn et al teach a method of screening compounds for the ability to increase glucose transport activity in mammalian cells (e.g., in skeletal muscle cells, in particular) and for the ability to increase cytoplasmic  $\text{Ca}^{2+}$  by accelerating the release of  $\text{Ca}^{2+}$  from the sarcoplasmic reticulum, or SR, into the cells (i.e., increasing store-mediated  $\text{Ca}^{2+}$  entry into the cell). Youn et al teach that rat skeletal muscle cells are preloaded with tagged calcium and then contacted with the compound W-7, (N-(6-aminohexyl)-5-

Art Unit: 1652

chloro-1-naphthalenesulfonamide), which induces release of  $\text{Ca}^{2+}$  from the SR into the cytoplasm. Youn et al teach that insulin is provided in the assays for glucose transport and calcium depletion (see, for example page C555, col. 2), therefore teaching that insulin-stimulated glucose transport is evaluated in the assays (see, for example, Abstract, pg. C556 col. 1, pg. C557 col. 1-2, pg. C559 col. 1-2, and pg. C560 col. 1-2).

Therefore, the reference is deemed to anticipate the instant claims above.

### ***Conclusion***

No claims allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMANDA P. WOOD whose telephone number is (571)272-8141. The examiner can normally be reached on M-F 8:30AM -5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on (571) 272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

APW  
Examiner  
Art Unit 1657

/Robert B Mondesi/  
Primary Examiner, Art Unit 1652